Mark Clark Appointed as New Chair of Prostate Cancer Research

We are pleased to announce the appointment of Mark Clark as the new Chair of Prostate Cancer Research (“PCR”). Mark will take over from Matthew Ellis, who steps down after six years in the role.

Mark has been a Trustee of PCR since 2019. He brings a combination of financial, scientific and governance experience as well as a strong commitment to improving the lives of men with prostate cancer, making him an ideal leader to guide our mission forward.

Mark expressed his gratitude and excitement for the opportunity, stating, “I am deeply honoured to step into the role of Chair at Prostate Cancer Research. Despite recent medical advances, prostate cancer continues to have a devastating impact, reflecting the absence of effective screening solutions, limited treatment options for advanced disease and inequities in access to care. I am committed to leveraging our resources and expertise to improve outcomes for patients and families affected by this disease.”

Matt has been a Trustee of PCR since 2016 and was appointed Chair in 2018. During this time, PCR has significantly increased the amount research that it funds and the breadth of its activities.  “It has been an incredible journey serving as Chair of Prostate Cancer Research” Matt remarked. “I am immensely proud of what the team has accomplished over the years, funding over 20 research projects at leading universities in the UK and the US, playing an important role in supporting translational research in the UK, and putting patients at the heart of our organisation as demonstrated by our pioneering work on racial and social inequalities in prostate cancer. Having worked together closely in recent months, I am delighted to be handing over to Mark to lead the organisation in an exciting new chapter.”

Oliver Kemp, CEO of Prostate Cancer Research, expressed gratitude for Matt’s commitment to PCR and expressed optimism for the future under Mark’s leadership. “Matt’s leadership has been instrumental in shaping PCR’s rapid growth and impact. We extend our heartfelt thanks for his dedication and wise counsel over the years. With Mark at the helm, I am confident that Prostate Cancer Research will continue to drive innovation, foster collaboration, and make meaningful strides in the fight against prostate cancer.”

For media inquiries, please contact:

[[email protected]]